IL-15 has been reported as tolerable for use in patients with metastatic melanoma or metastatic renal cell carcinoma, with patients showing altered homeostasis of NK cells, γδ T cells and CD8+ T cells in peripheral blood after treatment [38]. This evidence concerns the gene CD8A and metastatic melanoma.